Star Therapeutics
Adam Rosenthal is a seasoned entrepreneur and executive in the biotechnology sector, serving as CEO and Founder of Star Therapeutics, as well as CEO and Co-Founder of Vega Therapeutics since 2018. In addition, Adam Rosenthal is the Co-Founder and Director of Electra Therapeutics, holding the position of Founding CEO. Previously, Adam Rosenthal was the Chief Business Officer at True North Therapeutics, where the company was acquired by Bioverativ in an $825 million transaction. Other notable roles include serving as VP and Head of Corporate Development at iPierian, which was acquired by Bristol-Myers Squibb in a $725 million deal. Early career experience includes a position as Project Leader at The Boston Consulting Group. Adam Rosenthal holds a PhD in Biomedical Engineering and multiple degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology and Harvard Medical School.
This person is not in any teams
This person is not in any offices
Star Therapeutics
Star Therapeutics is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Our innovation engine starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within our portfolio to be unveiled, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Employees
11-50